# Junta clínica — PT-pseudo_e5104a16c8bb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e5104a16c8bb",
  "pid": "PT-pseudo_e5104a16c8bb",
  "task": 1,
  "psa": 4.4,
  "age": 60,
  "months": 3,
  "pirads": "5",
  "psad": 0.12,
  "psav": 0.31,
  "psap": 3.9,
  "vol": 34.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.84688765,
  "medhx": "Osteoarthritis, Atrial fibrillation",
  "meds": "apixaban, metoprolol",
  "notes": "PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 34 mL. csPCa 0.85.",
  "pmhx": [
    "Osteoarthritis",
    "Atrial fibrillation"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "183 cm",
    "bmi": "29.6",
    "bp": "102/68 mmHg",
    "hr": "62 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "14 Jan 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current visit initiated to reassess established prostate malignancy following a recent rise in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At sixty years of age, this retired plumber first sought evaluation for an elevated prostate-specific antigen reading in early 2023, which ultimately led to a biopsy confirming ISUP GG 3 carcinoma. He currently denies any lower urinary tract symptoms, registering an IPSS score of zero, and maintains a strictly alcohol-free lifestyle. A non-smoker, he resides with his partner and follows a mostly sedentary daily routine, punctuated by occasional neighborhood strolls. His osteoarthritis remains stable and is controlled with paracetamol, while routine dental visits occur every six months without complication. Well-controlled atrial fibrillation is managed with apixaban and metoprolol. Morning clinic slots align best with his reliance on public transportation."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate gland presents with a smooth, symmetric contour and typical firmness. Palpation detects no focal nodularity or asymmetrical enlargement. General systemic assessment shows stable cardiovascular parameters, including blood pressure and heart rate, with no clinical evidence of disseminated disease or enlarged lymph nodes."
    }
  ],
  "occupation": "retired plumber",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Niece",
  "recent_other": [
    "Dental — biannual check-up"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e5104a16c8bb
Task: 1

Encounter: Urology - outpatient on 14 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 4.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 3.9 ng/mL
  - Prostate volume: 34.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84688765 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis, Atrial fibrillation
  - Problem list / PMHx: Osteoarthritis, Atrial fibrillation
  - Current medication: apixaban, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 34 mL. csPCa 0.85.

Vitals: weight 99 kg, height 183 cm, BMI 29.6, BP 102/68 mmHg, HR 62 bpm. Smoking: Non-smoker.

Chief complaint: Current visit initiated to reassess established prostate malignancy following a recent rise in prostate-specific antigen levels.

History: At sixty years of age, this retired plumber first sought evaluation for an elevated prostate-specific antigen reading in early 2023, which ultimately led to a biopsy confirming ISUP GG 3 carcinoma. He currently denies any lower urinary tract symptoms, registering an IPSS score of zero, and maintains a strictly alcohol-free lifestyle. A non-smoker, he resides with his partner and follows a mostly sedentary daily routine, punctuated by occasional neighborhood strolls. His osteoarthritis remains stable and is controlled with paracetamol, while routine dental visits occur every six months without complication. Well-controlled atrial fibrillation is managed with apixaban and metoprolol. Morning clinic slots align best with his reliance on public transportation.

Physical examination: DRE: The prostate gland presents with a smooth, symmetric contour and typical firmness. Palpation detects no focal nodularity or asymmetrical enlargement. General systemic assessment shows stable cardiovascular parameters, including blood pressure and heart rate, with no clinical evidence of disseminated disease or enlarged lymph nodes.

Patient info: retired plumber; Married; Lives with partner.
Next of kin: Niece.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Sedentary lifestyle, occasional walking; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.09 epistemic (95% band 0.36-0.70); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.44: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.48: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.64: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"

PRECEDENT: BIOPSY (weighted vote 0.66 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. "Applying a PSA-D cut-off of 0.15ng/mL/cc, 817 biopsy procedures (58.4%) would have been avoided, at the cost of missing ISUP GG ≥ 2 cancer in 91 men (6.5%), while ISUP GG 1 cancer would not have been detected in 115 men (8.2%) [385]." This requires assessing the patient against this risk-based matrix.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of biopsy is not settled because the guideline emphasizes that the decision depends on a risk-based pathway, which means the panel variables alone do not determine the outcome. EXPERT-COHORT, the criterion you identified—that the prior positive biopsy means the panel alone is insufficient—is correct, but the guideline directs us to look at the documented grade of the prior biopsy and surveillance history, which is what the Registrar is tasked to find.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline suggests that PSA velocity is a factor in risk stratification, which must be considered in the risk-based pathway.
laboratory_results - the PSA density: the guideline explicitly links PSA density to the risk-based matrix for biopsy decisions.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the documented grade of the prior biopsy and the surveillance plan, as the guideline emphasizes this risk-based pathway.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require re-sampling?
  psa_trend (get_psa_trend) -> What is the PSA velocity and how does it factor into the risk stratification?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy and the surveillance protocol status?
  laboratory_results (get_lab_results) -> What is the PSA density and how does it fit into the risk-based matrix?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size of roughly 14 x 11 x 10 mm in the left peripheral zone spanning the base to mid-gland region.

psa_trend
What is the PSA velocity and how does it factor into the risk stratification?
PSA velocity: The trend shows a rise from 1.2 ng/mL in Mar 2023 to 4.4 ng/mL in Jan 2025.

previous_notes
What is the documented grade of the prior biopsy and the surveillance protocol status?
The documented grade of the prior biopsy is Gleason 4+3 disease, and the surveillance protocol status is routine laboratory monitoring without intervention.

laboratory_results
What is the PSA density and how does it fit into the risk-based matrix?
The PSA density is 0.12 ng/mL/mL, which fits into the risk-based matrix discussed by the EAU guideline.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already detailed the relevant history regarding the prior biopsy and clinical course.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding from the mpMRI suggests a high probability of significant prostate cancer.
PSA velocity shows a significant rise, indicating ongoing biological activity.

AGAINST sampling this patient now
The documented grade of the prior biopsy is Gleason 4+3 disease, which is a known outcome.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.40 ng/mL over 4 points spanning 22 months; velocity +1.73 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.7 ng/mL, conformal 95% band 1.9-23.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.81), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.53  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.62  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.66  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 3 ("Gleason 4+3")

RULE THAT FIRED: documented prior grade GG 3 (Gleason 4+3) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have answered both moderator questions. The `previous_notes` stated the documented grade was Gleason 4+3 disease, and the surveillance protocol status was routine laboratory monitoring without intervention.

ALIGNMENT WITH THE PANEL
The retrieved finding, documented prior grade of Gleason 4+3 disease, aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? Answered by the `previous_notes`: Gleason 4+3 disease. Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: routine laboratory monitoring without intervention.

WHAT CARRIES WEIGHT, AND WHY
The documented prior grade (Gleason 4+3) is the most critical variable because the PANEL-PROTOCOL explicitly states this finding dictates the decision, overriding the other expert opinions.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as NO BIOPSY, firmly based on the documented Gleason 4+3 disease found in the previous notes, which is the rule that fired in the PANEL-PROTOCOL.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

60y/PSA 4.4/PSAD 0.12, PI-RADS 5, prior biopsy Gleason 4+3 documented. Given documented prior grade, repeat biopsy is not indicated. The PI-RADS 5 finding is expected in this context, and management proceeds to treatment planning.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
